Mackay Martin
SEC-identified person · CIK 1414815 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Charles River Laboratories International, INC. CRL | Director | filed 2017–2026 |
| Kailera Therapeutics, Inc. KLRA | Director | filed 2026–2026 |
| Rallybio Corp RLYB | Director · Executive Chairman | filed 2021–2026 |
| Springworks Therapeutics, Inc. [SWTX | Director | filed 2024–2025 |
| 5:01 Acquisition Corp. FVAM | Director | filed 2020–2020 |
| Alexion Pharmaceuticals, INC. alxn | EVP & Global Head of R&D | filed 2013–2017 |
| Pfizer INC pfe | Senior Vice President | filed 2007–2010 |
| Encysive Pharmaceuticals INC ENCY | Director | filed 2008–2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.